Azithromycin is not associated with QT prolongation in hospitalized patients with community-acquired pneumonia
- 2 August 2015
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 24 (10), 1042-1048
- https://doi.org/10.1002/pds.3842
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Association of Azithromycin With Mortality and Cardiovascular Events Among Older Patients Hospitalized With PneumoniaJama-Journal Of The American Medical Association, 2014
- Cardiac diseases complicating community-acquired pneumoniaCurrent Opinion in Infectious Diseases, 2014
- Use of Azithromycin and Death from Cardiovascular CausesNew England Journal of Medicine, 2013
- Azithromycin and the Risk of Cardiovascular DeathNew England Journal of Medicine, 2012
- Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factorsJournal of Interventional Cardiac Electrophysiology, 2007
- QT Prolongation Associated with Azithromycin/Amiodarone CombinationPacing and Clinical Electrophysiology, 2001
- Comparative Pharmacodynamic Analysis of Q-T Interval Prolongation Induced by the Macrolides Clarithromycin, Roxithromycin, and Azithromycin in RatsAntimicrobial Agents and Chemotherapy, 2000
- QT prolongation due to roxithromycinPostgraduate Medical Journal, 2000
- A Prediction Rule to Identify Low-Risk Patients with Community-Acquired PneumoniaNew England Journal of Medicine, 1997
- Erythromycin-induced polymorphous ventricular tachycardia with normal QT intervalAmerican Heart Journal, 1996